PremiumThe FlyOvid Therapeutics sees cash runway into 2H26 Ovid Therapeutics Advances Pipeline Amid Financial Progress Ovid Therapeutics price target lowered to $4 from $5 at BTIG PremiumCompany AnnouncementsOvid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies Ovid Therapeutics sees cash runway into 2H26 Ovid Therapeutics reports Q4 EPS (13c), consensus (17c) PremiumThe FlyOvid to present posters on pipeline program for neuronal hyperexcitability Ovid Therapeutics reports Q3 EPS (20c), consensus (20c) Ovid Therapeutics presents study results on OV329 
